This project will focus on investigation of the molecular pathogenesis underlying mild cognitive impairment (MCI) prior to the onset of Alzheimer's disease (AD). Synapse and cholinergic enzyme (choline acetyltransferase;ChAT) activity losses correlate strongly with cognitive decline in AD. What precipitates these deficits, their time of onset, and first location during the progression of AD is currently unknown. One possible mechanism involves brain accumulation of soluble and insoluble forms of amyloid-beta peptide (A3), recently shown to impair synaptic function and correlate with cognitive decline. PET imaging using Pittsburgh Compound B (PiB;an amyloid-binding ligand) has identified prefrontal, posterior cingulate and precuneus cortex as the first brain regions to accumulate AP plaques in vivo. Whether this early amyloid pathology is associated with regional changes in synapse number and ChAT activity levels during the progression of AD is unknown. The present application will test several interrelated hypotheses, that in these vulnerable brain areas (1) there is a reduction in synapse number and synaptic proteins as determined by unbiased ultrastructural stereology and western blotting, respectively;(2) ChAT activity is reduced (determined by quantitative biochemistry and immunohistochemistry), and (3) these morphologic and biochemical changes correlate with regional Ap load (determined by quantitative ELISA and in vitro [H-3]PiB binding) and with cognitive changes in NCI, MCI and mild AD. The exciting finding that in vitro [H-3]PiB binding and in vivo PiB retention on PET scans correlate strongly (see Preliminary data) will enable us to construct """"""""virtual PiB scans"""""""" post-mortem, and correlate them with behavioral, cholinergic, and synaptic status. Such data will enhance future clinical evaluations with PiB PET imaging. The significance of these observations in those NCI subjects displaying significant amounts of Ap pathology (possible """"""""presymptomatic"""""""" AD), is of immense importance for determining the pathological interactions of Ap with cholinergic and synaptic alterations prior to first manifestations of clinical symptoms. The insight into how AP accumulation influences and relates to cholinergic/synaptic dysfunction, and how they all relate to clinical symptoms during disease progression, will facilitate development of stage-specific therapies for AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG014449-14
Application #
8247733
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
14
Fiscal Year
2011
Total Cost
$228,359
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Jansen, Willemijn J; Wilson, Robert S; Visser, Pieter Jelle et al. (2018) Age and the association of dementia-related pathology with trajectories of cognitive decline. Neurobiol Aging 61:138-145
Tiernan, Chelsea T; Mufson, Elliott J; Kanaan, Nicholas M et al. (2018) Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. J Neuropathol Exp Neurol 77:246-259
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Malek-Ahmadi, Michael; Chen, Kewei; Perez, Sylvia E et al. (2018) Cognitive composite score association with Alzheimer's disease plaque and tangle pathology. Alzheimers Res Ther 10:90
Edler, Melissa K; Sherwood, Chet C; Meindl, Richard S et al. (2018) Microglia changes associated to Alzheimer's disease pathology in aged chimpanzees. J Comp Neurol 526:2921-2936
Mahady, Laura; Nadeem, Muhammad; Malek-Ahmadi, Michael et al. (2018) Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. J Alzheimers Dis 62:115-131
Mufson, Elliott J; He, Bin; Ginsberg, Stephen D et al. (2018) Gene Profiling of Nucleus Basalis Tau Containing Neurons in Chronic Traumatic Encephalopathy: A Chronic Effects of Neurotrauma Consortium Study. J Neurotrauma 35:1260-1271
Alldred, Melissa J; Chao, Helen M; Lee, Sang Han et al. (2018) CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation. Hippocampus 28:251-268
Jeanneteau, Freddy; Barrère, Christian; Vos, Mariska et al. (2018) The Stress-Induced Transcription Factor NR4A1 Adjusts Mitochondrial Function and Synapse Number in Prefrontal Cortex. J Neurosci 38:1335-1350
Mahady, L; Nadeem, M; Malek-Ahmadi, M et al. (2018) HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease. Neuropathol Appl Neurobiol :

Showing the most recent 10 out of 293 publications